Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
RC48-ADC enhances immunotherapy by regulating PD-L1 through the Hippo-TAZ pathway and reactivating CD8+T cells, offering a novel combination therapeutic strategy for bladder cancer.
Authors
- Zefu Liu (ORCID: https://orcid.org/0009-0000-9722-1587)
- Zhenyu Nie (ORCID: https://orcid.org/0000-0003-2172-7957)
- Jinliang Huang (ORCID: https://orcid.org/0000-0002-0895-3418)
- Zhenglin Yi (ORCID: https://orcid.org/0000-0002-7768-1938)
- Luzhe Yan
- Xin Gao (ORCID: https://orcid.org/0000-0003-0877-0643)
- Jiatong Xiao
- Zhiyong Cai
- Jiao Hu (ORCID: https://orcid.org/0000-0003-4226-6416)
- Zhi Liu (ORCID: https://orcid.org/0000-0002-2247-8991)
- Chunyu Zhang (ORCID: https://orcid.org/0000-0003-0366-3515)
- Jinbo Chen (ORCID: https://orcid.org/0009-0009-2049-6342)
- Jinhui Liu (ORCID: https://orcid.org/0000-0001-8032-5099)
- Haisu Liang
- Bingquan Wu
Institutions
- Central South University (CN)
- Guiyang Medical University (CN)
- Hunan Normal University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Xiangya Hospital Central South University (CN)
- Huazhong University of Science and Technology (CN)
- Hunan First Normal University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2025-011881
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hunan Province